MBRX Moleculin Biotech, Inc.
NEUTRAL
Impact: 4/10
8-K
8-K context-dependent: Items 7.01
Latest settled — T+5d
MBRX ▲ +7.76% at T+5d
NEUTRAL call ✓ call won +7.76% · α vs SPY +6.67% · entry $2.45 → $2.64
Last close $2.47 (close Jun 8) · +0.82% from $2.45 entry
T+1d
+9.18%
call +9.18% · α +9.23%
$2.68
settled 15d ago
T+5d
+7.76%
call +7.76% · α +6.67%
$2.64
settled 9d ago
T+20d
—
call — · α —
—
in 13d
T+60d
—
call — · α —
—
in 2mo
Price Chart
Loading chart...
Executive Summary
Moleculin announced that an abstract on pooled cardiac safety data for Annamycin has been accepted for a poster presentation at the 2026 ASCO Annual Meeting. The data show no cardiotoxicity signals in 90 patients, supporting the drug's safety profile. This is a routine clinical update with no new efficacy or financial data.
Actionable Insight
Monitor ASCO presentation for detailed data; no immediate trading catalyst. The safety data reinforces Annamycin's profile but does not change near-term fundamentals.
Key Facts
- Abstract accepted for poster presentation at ASCO 2026 (May 29–June 2, 2026).
- Pooled cardiac safety data from 90 patients across 5 trials: no statistically significant LVEF change (mean difference -0.12%, p=0.84).
- Median cumulative Annamycin dose 660 mg/m² (range 210–2,970 mg/m²), exceeding conventional anthracycline limits.
- No evidence of drug-induced cardiotoxicity by ECG, biomarkers, or adverse events.
- Previously reported Phase 1b/2 data: 50% CR, 60% CRc, median OS 12.39 months.
Financial Impact
No financial impact disclosed.
Risk Factors
- Clinical trial risks for ongoing Phase 2b/3 MIRACLE trial.
- Need for additional financing as noted in forward-looking statements.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-018242 |
| Exhibit: ex_967284.htm | 0001437749-26-018242 |
| Document: 0001437749-26-018242-index-headers.html | 0001437749-26-018242 |
| Document: 0001437749-26-018242-index.html | 0001437749-26-018242 |
| Document: 0001437749-26-018242.txt | 0001437749-26-018242 |
13 reports for MBRX
50%
Hit rate
best @ T+5▲ +9.81%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
8-K
| $2.58 awaiting T+5 | awaiting T+5 | — | $2.47 (−4.26%) |
|
May 29, 2026
11d ago
|
8-K
| $2.79 $2.46 | ▼ −11.83% | ▼ −11.54% | $2.47 (−11.47%) |
|
May 26, 2026
14d ago
|
8-K
| $2.45 $2.64 | ▲ +7.76% | ▲ +6.67% | $2.47 (+0.82%) |
|
May 22, 2026
18d ago
|
8-K
| $2.45 $2.64 | ▲ +7.76% | ▲ +6.67% | $2.47 (+0.82%) |
|
May 15, 2026
25d ago
|
8-K
| $2.11 $2.39 | ▲ +13.27% | ▲ +12.31% | $2.47 (+17.06%) |
|
May 15, 2026
25d ago
|
Press Release
| $2.11 $2.39 | ▼ −13.27% | ▼ −12.31% | $2.47 (−17.06%) |
|
May 13, 2026
27d ago
|
8-K
| $2.14 $2.35 | ▲ +9.81% | ▲ +10.97% | $2.47 (+15.42%) |
|
May 12, 2026
28d ago
|
8-K
| $2.34 $2.09 | ▼ −10.68% | ▼ −10.76% | $2.47 (+5.56%) |
|
May 8, 2026
4w ago
|
8-K
| $2.47 $2.20 | ▼ −10.93% | ▼ −12.39% | $2.47 (+0.00%) |
|
Apr 23, 2026
6w ago
|
8-K
| $2.54 $2.51 | ▼ −1.18% | ▼ −2.66% | $2.47 (−2.76%) |
Showing 10 of 13
US Market Status
Market Closed — Opens in 7h 17m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access